organization · Reporting owner
Coastlands Capital LP
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC.ADIL · Entity 7742 | 10% owner | July 14, 2026 | July 16, 2026 |
| Pasithea Therapeutics Corp.KTTA · Entity 7685 | 10% owner | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADIAL PHARMACEUTICALS, INC.
Report date July 14, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Coastlands Capital LP | 388,308 |
Last balance in matching sequence
After 2026-07-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-07-14 · Purchase · Acquired 2,000 · Balance 387,075 F1: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein. Row 2 · 2026-07-16 · Purchase · Acquired 1,233 · Balance 388,308 F1: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.
Pasithea Therapeutics Corp.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Coastlands Capital LP | 3,835,035 |
Reported balance
After 2026-06-17 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-17 · Purchase · Acquired 100,000 · Balance 3,835,035 F1: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eloxx Pharmaceuticals, Inc.
Report date May 27, 2026 · Filed May 30, 2026
Section 16 reporting ended · disclosed 2026-05-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Coastlands Capital LP | 0 |
Reported balance
After 2026-05-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-27 · Other · Disposed 1,250,000 · Balance 0 F1: Pursuant to the terms of that certain Amended and Restated Pre-Funded Warrant to Purchase Common Stock, dated as of April 27, 2026, Coastlands Capital Partners LP (the "Partnership"), exchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer. F2: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of the Partnership. Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein. |
| Pre-funded WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 | IndirectBy Coastlands Capital LP | 30,612,243 |
Reported balance
After 2026-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-27 · Other · Acquired 1,250,000 · Balance 30,612,243 F1: Pursuant to the terms of that certain Amended and Restated Pre-Funded Warrant to Purchase Common Stock, dated as of April 27, 2026, Coastlands Capital Partners LP (the "Partnership"), exchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer. F3: The pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F2: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of the Partnership. Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Amended and Restated Pre-Funded Warrant to Purchase Common Stock, dated as of April 27, 2026, Coastlands Capital Partners LP (the "Partnership"), exchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer.
F2: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of the Partnership. Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.
F3: The pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 16, 2026 21:08 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 1,233 | $2.75 | $3,390.75 |
DisclosureSEC source: 0001104659-26-084300 · tm2620655-1_4seq1.xml · nonDerivative · entry 2 Coastlands Capital LP · CIK 0002068530 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Coastlands Capital LP Disclosed balance after: 388,308 F1 · ownership.nature: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein. Read SEC document |
| July 14, 2026 Filed Jul 16, 2026 21:08 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 2,000 | $2.65 | $5,300.00 |
DisclosureSEC source: 0001104659-26-084300 · tm2620655-1_4seq1.xml · nonDerivative · entry 1 Coastlands Capital LP · CIK 0002068530 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Coastlands Capital LP Disclosed balance after: 387,075 F1 · ownership.nature: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein. Read SEC document |
| July 10, 2026 Filed Jul 13, 2026 14:30 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 1,700 | $2.70 | $4,590.00 |
DisclosureSEC source: 0001104659-26-082972 · tm2620210-1_4seq1.xml · nonDerivative · entry 2 Coastlands Capital LP · CIK 0002068530 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Coastlands Capital LP Disclosed balance after: 385,075 F1 · ownership.nature: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 14:30 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 10,053 | $2.79 | $28,047.87 |
DisclosureSEC source: 0001104659-26-082972 · tm2620210-1_4seq1.xml · nonDerivative · entry 1 Coastlands Capital LP · CIK 0002068530 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Coastlands Capital LP Disclosed balance after: 383,375 F1 · ownership.nature: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 14:30 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 25,000 | $2.60 | $65,000.00 |
DisclosureSEC source: 0001104659-26-079686 · tm2619520-1_4seq1.xml · nonDerivative · entry 1 Coastlands Capital LP · CIK 0002068530 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Coastlands Capital LP Disclosed balance after: 373,322 F1 · ownership.nature: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 14:30 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | PurchaseCommon Stock | 100,000 | $0.53 | $53,000.00 |
DisclosureSEC source: 0001104659-26-076184 · tm2618440-1_4seq1.xml · nonDerivative · entry 1 Coastlands Capital LP · CIK 0002068530 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Coastlands Capital LP Disclosed balance after: 3,835,035 F1 · ownership.nature: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein. Read SEC document |
| May 27, 2026 Filed May 30, 2026 01:55 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | OtherPre-funded Warrant · Derivative | 1,250,000 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001104659-26-068440 · tm2615865-2_4seq1.xml · derivative · entry 2 Coastlands Capital LP · CIK 0002068530 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Coastlands Capital LP Disclosed balance after: 30,612,243 Underlying: Common Stock · 1,250,000 shares Expires not disclosed F1 · kind: Pursuant to the terms of that certain Amended and Restated Pre-Funded Warrant to Purchase Common Stock, dated as of April 27, 2026, Coastlands Capital Partners LP (the "Partnership"), exchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer. F3 · derivative.exercise_date: The pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F3 · derivative.expiration_date: The pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F2 · ownership.nature: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of the Partnership. Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein. Read SEC document |
| May 27, 2026 Filed May 30, 2026 01:55 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | OtherCommon Stock | 1,250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-068440 · tm2615865-2_4seq1.xml · nonDerivative · entry 1 Coastlands Capital LP · CIK 0002068530 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Coastlands Capital LP Disclosed balance after: 0 F1 · kind: Pursuant to the terms of that certain Amended and Restated Pre-Funded Warrant to Purchase Common Stock, dated as of April 27, 2026, Coastlands Capital Partners LP (the "Partnership"), exchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer. F2 · ownership.nature: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of the Partnership. Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.